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Abstract
Streptococcus pneumoniae causes respiratory and other invasive infections. Increased resistance of this bacterium to antibiotics
necessitates new approaches to the treatment of infections. Attachment of bacteria to human pharyngeal epithelial cells is the initial step in
the pathogenesis of infection and S-carboxymethylcysteine (S-CMC) can modulate the attachment of Moraxella catarrhalis and nontypable
Haemophilus influenzae to epithelial cells. Unlike these two, S. pneumoniae is gram-positive and has a well-defined capsule. Here we
examined the effects of S-CMC on the attachment and detachment of S. pneumoniae to human pharyngeal epithelial cells in vitro. Treatment
of these cells with S-CMC significantly reduced the number of attached S. pneumoniae. S-CMC also resulted in a significant increase in the
detachment of already attached S. pneumoniae to epithelial cells. In addition, treatment of S. pneumoniae with S-CMC significantly reduced
their ability to attach to epithelial cells, but not the number of viable bacteria. Our study shows that S-CMC modulates the attachment of
S. pneumoniae to human pharyngeal epithelial cells by acting both on cells and bacteria.
q 2003 Elsevier Science Ltd. All rights reserved.
Keywords: Respiratory infection; Bacterial attachment; Mucosa; Epithelial cells; Bacterial adherence
1. Introduction
Attachment of bacteria to host epithelial cells is the first
step in the pathogenesis of bacterial infections. Strepto-
coccus pneumoniae is one of the major groups of bacteria
that can cause various invasive and noninvasive infections.
Most of these infections are preceded by colonization of
the pharynx by S. pneumoniae. Then either the bacteria
invade the lower respiratory tract causing bronchopneu-
monia and subsequently invade the blood stream or remain
localized and cause infection of the mucosal tissue. In
severe cases, the colonized bacterium may invade the
upper airways directly to cause meningitis. Therefore,
inhibition of bacterial colonization in the pharyngeal area
seems to be a useful strategy to prevent infections. This
may be achieved by either systemic or local use of anti-
attachment agents such as antibodies, receptor analogues or
other agents such as xylitol [1], N-acetylcysteine [2] and
S-carboxymethylcysteine (S-CMC). Among these, S-CMC
is perhaps the most promising agent since previous studies
have shown that it significantly reduced the number of
episodes of acute exacerbations of respiratory infections
when administered systemically [3]. Previous studies have
also demonstrated that S-CMC acts both in vitro and in
vivo, by rendering pharyngeal epithelial cells capable of
inhibiting the adhesion of M. catarrhalis and nontypable
Hemophilus influenzae (NTHI) [4,5].
S-CMC is a mucolytic agent and has been used in the
treatment of different respiratory diseases characterized by
abnormal mucus secretion [4,5]. It is also effective for the
treatment of otitis media with effusion in children [6]. The
precise mode of action of S-CMC is unknown; it corrects
the intracellular abnormalities of glycoprotein synthesis
and normalizes the secretory function of the mucosal
epithelium [7].
To our knowledge, the effects of S-CMC on gram-
positive bacteria and bacteria with a well-defined capsule
have not been investigated. These features apply to
S. pneumoniae, which is also one of the most significant
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pathogens known to cause respiratory tract infections.
Furthermore, the increased number of antibiotic-resistant
S. pneumoniae makes treatment of infections caused by such
bacteria difficult to control with commonly used antibiotics.
The present study was designed to examine the effects of
S-CMC on the attachment of S. pneumoniae to pharyngeal
epithelial cells. Our results indicated that S-CMC could
modulate the attachment of S. pneumoniae to human
pharyngeal epithelial cells by acting both on the cells and
bacteria. The results suggest that this drug may be potentially
useful for the prevention of S. pneumoniae infections.
2. Results
2.1. S-CMC inhibits attachment of S. pneumoniae
to epithelial cells
Taking all the data of controls into consideration, the
mean number of S. pneumoniae strain SP-95-19 attached per
epithelial cells was 17.0 ^ 8.1. The attachment of this strain
to epithelial cells significantly decreased following treat-
ment of the cells with S-CMC at a concentration of 100, 10,
1 or 0.1 mg/ml (P , 0:05; Table 1). However, at 0.01 and
0.001 mg/ml, S-CMC had no effect on attachment. Treat-
ment of pharyngeal epithelial cells with S-CMC at a
concentration of 0.1 mg/ml resulted in a significant ðP ,
0:001Þ decrease in the attachment of the other three strains
of S. pneumoniae (SP-95-27, SP-96-29 and SP-95-36) to
33.9 ^ 0.8% of the control.
2.2. S-CMC enhances detachment of bacteria from
epithelial cells
Following the completion of the attachment assay,
epithelial cells with the attached S. pneumoniae strain SP-
95-19 were treated with 100, 10, 1 or 0.1 mg/ml S-CMC.
This resulted in a significant decrease in the number of
attached bacteria (Table 2). However, no such decrease was
noted when cells were treated with 0.01 and 0.001 mg/ml S-
CMC (Table 2).
The detachment assay also showed a significant ðP ,
0:05Þ decrease in the proportion of the other three strains of
S. pneumoniae (SP-95-27, SP-96-29 and SP-95-36) to
44.3 ^ 17.3% of the control, when pharyngeal epithelial
cells with the attached bacteria were treated with 0.1 mg/ml
S-CMC.
2.3. Effects of S-CMC treatment of bacteria on attachment
to epithelial cells
S-CMC treatment did not change the cell wall or Gram
staining pattern of S. pneumoniae. Treatment of S.
pneumoniae strain SP-95-19 with 10 or 1 mg/ml S-CMC
significantly decreased the number of bacteria attached to
epithelial cells (Table 3). However, at concentrations of 0.1
and 0.01 mg /ml, S-CMC had no significant effect on the
number of attached bacteria.
Treatment of the other three strains of S. pneumoniae
(SP-95-27, SP-96-29 and SP-95-36) with 10 mg/ml of
Table 1
Effects of S-carboxymethylcysteine treatment of pharyngeal epithelial cells






P value Number of
experiments
17.8 ^ 10.1 5.1 ^ 2.6 (100) 71.3 ,0.05 6
20.2 ^ 10.2 6.9 ^ 3.4 (10) 65.8 ,0.05 6
19.0 ^ 9.9 8.3 ^ 4.6 (1) 56.3 ,0.05 7
19.0 ^ 9.9 8.4 ^ 3.8 (0.1) 55.8 ,0.05 7
11.3 ^ 1.9 8.6 ^ 5.8 (0.01) 23.9 NS 4
15.0 ^ 5.5 12.7 ^ 4.1 (0.001) 16.7 NS 3
Attachment is expressed as number of bacteria attached per pharyngeal
epithelial cell. Each experiment was performed in duplicate. For a given
concentration of S-CMC treatment, experiments were done in separate
days. P values are for comparisons with the control. NS, not significant.
Table 2
Effects of S-carboxymethylcysteine on detachment of S. pneumoniae strain






P value Number of
experiments
8.9 ^ 2.7 3.4 ^ 3.1 (100) 69.7 ,0.005 5
8.9 ^ 2.4 2.6 ^ 1.7 (10) 70.8 ,0.005 5
8.9 ^ 2.4 2.7 ^ 1.5 (1) 69.7 ,0.005 5
8.2 ^ 2.9 2.5 ^ 1.4 (0.1) 69.5 ,0.05 3
10.4 ^ 1.0 11.7 ^ 1.7 (0.01) ND NS 3
10.4 ^ 1.0 9.4 ^ 1.0 (0.001) 9.6 NS 3
Detachment is expressed as number of attached bacteria per pharyngeal
epithelial cell after detachment assay. Each experiment was performed in
duplicate. For a given concentration of S-CMC treatment, experiments were
done in separate days. P values are for comparisons with the control. ND,
no decrease; NS, not significant.
Table 3
Effects of S-carboxymethylcysteine treatment of S. pneumoniae strain SP-
95-19 on their attachment to human pharyngeal epithelial cells
S-CMC concen
tration (mg/ml)
Attachment Decrease in mean
attachment (%)
P value
0 (Control) 31.6 ^ 8.0
10 16.8 ^ 11.2 46.8% ,0.01
1 19.7 ^ 8.5 37.7% ,0.001
0.1 21.1 ^ 8.6 33.2% NS
0.01 37.8 ^ 11.4 ND NS
Attachment is expressed as number of bacteria attached per pharyngeal
epithelial cell. A total of four experiments were performed at each
concentration. For a given concentration of S-CMC treatment, experiments
were done in separate days. P values are for comparisons with the control.
NS, not significant; ND, no decrease.
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S-CMC resulted in a significant ðp , 0:001Þ decrease in the
number of attached bacteria to 37.1 ^ 1.7% of the control.
However, the effect was variable when these strains when
treated with 1 mg/ml of S-CMC. In strain SP-95-27, SP-96-
29 and SP-95-36, the attachment decreased to 34.4%, 14.6%
and 1.1% of the control, respectively.
2.4. S-CMC has no effect on viability of bacteria
Treatment of S. pneumoniae with S-CMC did not affect the
viability of bacteria relative to the control (data not shown).
3. Discussion
Although the pneumococcal polysaccharide vaccine has
been licensed for the last 20 years in the US and UK,
the effectiveness of this vaccine in preventing infections in
the vulnerable population is not satisfactory [8]. In addition,
the worldwide spread of penicillin-resistant S. pneumoniae
emphasizes the need for new approaches to prevent such
bacterial infections [9]. The use of a drug that can block S.
pneumoniae attachment to epithelial cells represents a new
approach for the prevention and treatment of infections
caused by this microbe. In the present study, we showed that
S-CMC at a concentration achievable in the sputum [4]
inhibited the attachment of S. pneumoniae to human
pharyngeal epithelial cells in vitro as well the detachment
of the already attached S. pneumoniae from human
pharyngeal epithelial cells. The mechanism by which
S-CMC prevents the bacterial attachment is not known at
present. Since the suppression of attachment was also noted
for M. catarrhalis and NTHI, it is likely that S-CMC acts on
a common receptor, or it masks the receptor. Compared to
M. catarrhalis and NTHI [4,5], significant inhibition of
S. pneumoniae attachment was achieved when epithelial
cells were treated with low concentrations of S-CMC.
Moreover, detachment was also observed at relatively low
concentration of S-CMC compared with that of NTHI [5].
A two-step molecular model has been proposed for the
attachment of S. pneumoniae to eucaryotic cells [10] where
the initial encounter between pneumococci and naive host
cells is mediated by resting eucaryotic cell receptors. With
increasing numbers of bacteria, the induced inflammatory
response upregulates new eucaryotic cell receptors that
promote addition bacterial attachment. S-CMC appears to
have an anti-inflammatory function, probably through its
effect on sialomucin synthesis and subsequent kinin
inhibition [7]. It is still not clear whether S-CMC can
prevent such receptor upregulation by downregulating the
inflammatory response.
The most important and interesting finding of the present
study was the significant decrease in the attachment
following treatment of S. pneumoniae with S-CMC.
Certainly this effect was not due to any bactericidal effect
of S-CMC because our quantitative culture assays showed
that S-CMC had no effect on viable bacterial counts. In
addition the reduction in the attachment correlated well with
the dose of S-CMC used for the treatment of S. pneumoniae.
Our previous studies showed that S-CMC could not reduce
the attachment of M. catarrhalis and NTHI to epithelial
cells [4,5]. The mechanism of S-CMC-induced attenuation
of S. pneumoniae attachment to human pharyngeal epi-
thelial cells certainly deserves further investigation. We
previously showed that S-CMC could remove carbohydrate
from the cell surface [4]. Others have shown that N-acetyl-
L-cysteine, another mucolytic agent, successfully removed
the capsule of S. pneumoniae in transformation experiments
[11]. It is possible that the effect of S-CMC noted in the
present study was also due to the same mechanism.
S. pneumoniae has a well-established capsule in contrast
to NTHI and M. catarrhalis. In this regard, previous studies
showed that the adherence of noncapsulated forms of
S. pneumoniae to bronchial epithelial cells was stronger
than the capsulated parent strain [12]. On the other hand,
several proteins on S. pneumoniae cell wall, such as choline
binding proteins [13,14] and peptide permeases [10] have
been reported to act as adhesins assisting bacterial
attachment to human bronchial epithelial cell line. It should
be noted however, that cultured cells may express aberrant
receptor(s) because cell lines are prepared from cancer
tissues or modified by virus infection. It may be possible
that due to this noncapsulated S. pneumoniae attach more to
cultured cells than capsulated one. Since we are using cells
directly scraped from human pharynx, therefore, the
utilization of receptors by S. pneumoniae for attachment is
possibly different from cultured cells. Recently, Dagan and
colleagues [15] reported a significant decrease of nasophar-
yngeal carriage of S. pneumoniae after administration of a 9-
valent pneumococcal conjugate vaccine. It seems that
anticapsular antibodies prevented attachment and decrease
of colonization occurred. Therefore it is possible that the
bacterial capsule could play a role in the attachment to
human pharyngeal epithelial cells. Studies are currently
being conducted in our laboratories to determine the role of
S. pneumoniae capsule in their attachment to human
pharyngeal epithelial cells and the mechanism of action of
S-CMC on the capsule of S. pneumoniae.
The major pathogens causing respiratory infections are S.
pneumoniae, NTHI and M. catarrhalis [16]. It became clear
with this study that S-CMC reduces the number of episodes
of acute exacerbation of respiratory infections by rendering
pharyngeal epithelial cells capable of inhibiting the
attachment of all these major pathogens.
4. Materials and methods
4.1. Bacteria
The following strains of S. pneumoniae were used in
this study: strain SP-95-27 of serotype 9V isolated from
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post-mortem lung tissue; strain SP-95-19 of serotype 19F
isolated from the sputum of a patient with respiratory
infection; strain SP-96-29 of serotype 6B isolated from
secretion that accumulated inside the endotracheal tube
of an unconscious patient; and strain SP-95-36 of
serotype 14 isolated from throat swab of a patient.
Strain SP-95-19 was used in most experiments unless
otherwise stated. All strains were stocked in Mueller-
Hinton broth (Merck KgaA, Darmstadt, Germany)
containing 5% defibrinated rabbit blood and kept at
220 8C until use. For attachment studies, assay bacteria
were cultured overnight on Brain Heart Infusion agar
(Merck KgaA, Darmstadt, Germany) containing 7%
defibrinated rabbit blood at 37 8C in 5% CO2 incubator,
then the colony was transferred to Todd-Hewitt broth
(Difco Laboratories, Detroit, MI, USA) containing 0.5%
yeast extract and cultured in an incubator under constant
shaking at 37 8C for 6 h. This yielded a bacterial density
of 5 £ 107 cfu/ml of S. pneumoniae. For each experiment
this was confirmed by quantitative culture. The bacteria
were washed once in phosphate buffered saline (PBS),
pH 7.2, at 4 8C, by centrifugation at 3000g for 10 min
and then used for the attachment assay.
4.2. Pharyngeal epithelial cells
Pharyngeal epithelial cells were collected from a
consented normal healthy adult male by scraping the
oropharynx with a cotton swab. Cells from the swab were
collected in tubes containing 1/15 M phosphate buffer (PB,
pH 7.2). Cells were washed three times with PB, by
centrifugation at 80g for 10 min at room temperature.
Finally, pharyngeal epithelial cells were count with a Burker
chamber and adjusted to a density of 5 £ 104 cells/ml.
4.3. Attachment assay
The attachment assay was performed as described
previously [17] with minor modifications. Bacteria and
cells were mixed in equal proportions to a volume of 1 ml
and incubated for 30 min at 37 8C in a water bath under
constant shaking. The Unattached bacteria were then
removed by three washings using PBS by centrifugation at
80g for 10 min at room temperature. Finally, the cells were
collected on a glass slide by Cytospin (Thermo Shandon
International, UK). Smears were Gram-stained and viewed
under an oil immersion lens of a light microscope to count
the number of attached bacteria on 50 consecutive cells. For
each slide counting was done blindly.
4.4. Treatment of epithelial cells with S-CMC
For the attachment inhibition assay, pharyngeal epi-
thelial cells were treated with various concentrations of S-
CMC (100, 10, 1, 0.1, 0.01 and 0.001 mg/ml), and incubated
at 37 8C for 30 min in a water bath under constant shaking.
Then cells were washed three times with PB at 80g for
10 min at room temperature. Control cells were prepared in
a similar manner except they were not treated with S-CMC.
This was followed by conducting the aforementioned
attachment assay.
For the detachment assay the following procedure was
performed; after completion of the attachment assay,
epithelial cells were treated with various concentrations of
S-CMC (100, 10, 1, 0.1, 0.01 and 0.001 mg/ml) and
incubated at 37 8C for 30 min in a water bath under constant
shaking. Then cells were washed three times with PBS at
80g for 10 min at room temperature, to remove the detached
bacteria. Control cells were prepared in a similar manner
except they were not treated with S-CMC.
4.5. Treatment of bacteria with S-CMC
Bacteria at a density of 5 £ 107 cfu/ml were treated with
various concentrations of S-CMC (10, 1, 0.1, 0.01 and
0.001 mg/ml) at 37 8C for 30 min in a water bath under
constant shaking. Then the bacteria were washed three times
in PBS at 4 8C by centrifugation at 3000 rpm, each time for
10 min. Bacteria treated similarly but without any drug
represented the control sample. Attachment assay was
performed as described above and compared with the
control. After treatment with S-CMC, the viability of
S. pneumoniae was determined by quantitative cultures on
BHI agar containing 7% defibrinated rabbit blood. The
following day, the viability of bacteria was compared with
that of the control.
4.6. Statistical analysis
All data were expressed as mean ^ SD. Differences
between groups were examined for statistical significance
using Students t-test. Data were considered statistically
significant if the P value was lower than 0.05.
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